NEW YORK (GenomeWeb) – Melanoma test development firm DermTech International has filed to go public with a proposed offering of up to $25 million in stock.

The company filed its preliminary prospectus with the US Securities and Exchange Commission on Friday. It has not yet priced its shares or said how many shares it plans to offer.

DermTech plans to list its shares on the Nasdaq Capital Market under ticker symbol "DMTK." The underwriters on the offering are the Maxim Group and Feltl & Co.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.